To develop and validate a prognostic nomogram for patients with intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for non-metastatic upper tract urothelial carcinoma (UTUC).
The clinical data of 468 patients registered in the surveillance, epidemiology and end results database between 2010 and 2015 were retrospectively analyzed.
Multivariate analysis using the Cox proportional hazard model was used to determine independent prognostic factors for the development of a nomogram to predict the 1-, 3-, and 5-year probability of individual cancer-specific survival (CSS). Moreover, the nomogram was internally validated using receiver operating characteristic curves and calibration plots.
Age at IVR > 80 years, UTUC stage ≥ T3, bladder cancer (BC) stage T1, and muscle-invasive BC (stage ≥ T2) were identified as independent risk factors for CSS in patients with IVR after RNU, whereas a time interval of > 24 months between UTUC and BC was an independent protective factor. The 1-, 3-, and 5-year predictive accuracies of our nomogram were 0.74, 0.70, and 0.71, respectively. Additionally, 1-, 3-, and 5-year calibration curves demonstrated perfect agreement between the nomogram-predicted and the actual CSS.
This study developed and internally validated the first nomogram to date to predict individual prognosis in patients with IVR after RUN for UTUC. This nomogram can be used for patient counseling and for designing clinical trials.
World journal of urology. 2019 Oct 25 [Epub ahead of print]
Guangdong Hou, Yu Zheng, Lei Zhang, Dong Lai, Fuli Wang, Xi'an Li, Fei Yan, Jingyang Tian, Geng Zhang, Ping Meng, Di Wei, Zheng Zhu, Jiarui Yuan, Qiang Hui, Jianlin Yuan
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China., Department of Otorhinolaryngology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China., St. George's University School of Medicine, West Indies, Grenada., Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. .